<DOC>
	<DOCNO>NCT01701999</DOCNO>
	<brief_summary>Study rBV A/B-CL-001 Phase 2b , 2-part , open-label , uncontrolled study evaluate safety , tolerability , immunogenicity single dose recombinant botulinum vaccine A/B ( rBV A/B ) production BabyBIG volunteer previously immunize pentavalent botulinum ( PBT ) toxoid . This study design determine neutralize antibody level botulinum toxin type A B healthy subject previously immunize PBT occupational protection receive rBV A/B . Subjects titer neutralize antibody toxin would candidate plasma donation BabyBIG production .</brief_summary>
	<brief_title>Safety , Tolerability , Immunogenicity Study Investigational Recombinant Botulinum Vaccine A/B ( rBV A/B ) Volunteers Previously Immunized With Investigational Pentavalent Botulinum Toxoid</brief_title>
	<detailed_description />
	<mesh_term>Botulism</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>The volunteer receive pentavalent botulinum toxoid occupational protection BB IND 0161 , previous pentavalent botulinum toxoid dose least 6 month prior plan rBV A/B dose . The volunteer age 18 69 year time consent . The volunteer healthy acceptable medical history . The volunteer meet subject suitability requirement recommendation source plasma donor ( Part 2 subject ) . The volunteer , female childbearing potential , pregnant lactating , agree use acceptable form FDAapproved contraception duration study . The volunteer ability understand requirement study provide inform consent . The volunteer agree complete subject diary daily basis 7 day postvaccination report concomitant medication adverse event study period . The volunteer provide write authorization use disclosure protect health information . The volunteer agree donate blood blood product ( outside study procedure ) course study . The volunteer personal health insurance . Be pregnant nurse The volunteer history laboratory evidence syphilis , acquire immunodeficiency syndrome , CreutzfeldtJakob disease , infection human immunodeficiency viruses 1 2 , human T cell lymphotropic virus 1 , hepatitis B virus , hepatitis C virus . The volunteer prior severe local severe systemic reaction last immunization pentavalent botulinum toxoid . The volunteer know allergy aluminum compound , yeast , component vaccine . The volunteer donate one unit blood undergone plasmapheresis within 28 day screen . The volunteer receive blood product immunoglobulin within 6 month screen plan receive product study . The volunteer receive licensed nonliving vaccine within 14 day study entry license live vaccine within 60 day study entry . The volunteer receive investigational product ( drug , biologics , vaccine , implantable device ) 60 day prior study entry plan receive experimental product time study . The volunteer receive prescription immunosuppressive immunomodulatory agent , include parenteral , inhaled , oral corticosteroid within 3 month screen plan receive therapy time study exception ( Subjects use prescription topical steroid may enrol 2 week therapy complete ; Intraarticular , bursal , tendon injectable steroid permit ; Any overthecounter topical steroid use permit ; Ophthalmic intranasal steroid permit ) . The volunteer receive cytotoxic therapy time previous 5 year study entry . The volunteer active systemic recurrent disease would place subject unacceptable risk injury , require hospitalization , require surgical intervention . The volunteer history alcohol drug abuse within 12 month screen . The volunteer past , present , suspect illicit injection drug use . The volunteer inflammatory , vasculitic , rheumatic disease , include systemic lupus erythematosus , polymyalgia rheumatica , rheumatoid arthritis , scleroderma . The volunteer clinically recognize hepatic renal insufficiency . The volunteer uncontrolled hypertension . The volunteer moderate severe asthma , chronic obstructive pulmonary disease , significant pulmonary disease . The volunteer seizure disorder . The volunteer moderate severe illness oral temperature 100.4Â°F great within 3 day prior immunization . The volunteer determine investigator unsuitable participation trial reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Botulism Vaccine</keyword>
</DOC>